| Title |
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study
|
|---|---|
| Published in |
BMC Cancer, November 2018
|
| DOI | 10.1186/s12885-018-5101-3 |
| Pubmed ID | |
| Authors |
Ana Fernández, Mercedes Salgado, Adelaida García, Elvira Buxò, Ruth Vera, Jorge Adeva, Paula Jiménez-Fonseca, Guillermo Quintero, Cristina Llorca, Mamen Cañabate, Luis Jesús López, Andrés Muñoz, Patricia Ramírez, Paula González, Carlos López, Margarita Reboredo, Elena Gallardo, Manuel Sanchez-Cánovas, Javier Gallego, Carmen Guillén, Nuria Ruiz-Miravet, Víctor Navarro-Pérez, Juan De la Cámara, Inmaculada Alés-Díaz, Roberto Antonio Pazo-Cid, Alberto Carmona-Bayonas |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 63 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 12 | 19% |
| Student > Bachelor | 9 | 14% |
| Researcher | 9 | 14% |
| Student > Ph. D. Student | 6 | 10% |
| Student > Master | 4 | 6% |
| Other | 8 | 13% |
| Unknown | 15 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 32% |
| Biochemistry, Genetics and Molecular Biology | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Engineering | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Other | 9 | 14% |
| Unknown | 21 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 March 2019.
All research outputs
#13,632,418
of 23,116,036 outputs
Outputs from BMC Cancer
#3,028
of 8,390 outputs
Outputs of similar age
#215,531
of 437,974 outputs
Outputs of similar age from BMC Cancer
#57
of 207 outputs
Altmetric has tracked 23,116,036 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,390 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,974 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 207 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.